Genome ‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records
(Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 17, 2017 Category: Biomedical Science Authors: Jamie R. Robinson, Joshua C. Denny, Dan M. Roden, Sara L. Driest Tags: REVIEW Source Type: research
Repurposing Statins for Renal Protection: Is It a Class Effect?
Clinical and Translational Science,Volume 11, Issue 2, Page 100-102, March 2018. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Source Type: research
Factors Affecting Drug ‐Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan
Clinical and Translational Science,Volume 11, Issue 2, Page 182-188, March 2018. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Source Type: research
Repurposing Statins for Renal Protection: Is It a Class Effect?
Clinical and Translational Science,Volume 11, Issue 2, Page 100-102, March 2018. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Source Type: research
Factors Affecting Drug ‐Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan
Clinical and Translational Science,Volume 11, Issue 2, Page 182-188, March 2018. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Source Type: research
---
Clinical and Translational Science, Ahead of Print. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Source Type: research
Repurposing Statins for Renal Protection: Is It a Class Effect?
(Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Authors: Stephen J. McWilliam, Daniel J. Antoine, Munir Pirmohamed Tags: COMMENTARY Source Type: research
Factors Affecting Drug ‐Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan
Abstract
We assessed the current status of Asian global clinical trials (GCTs) and factors, such as therapeutic areas, main metabolic enzymes targeted, approval status in the United States or the European Union, development strategies, influencing drug‐development strategies in Asian GCTs and in general GCTs for drug approval in Japan. The findings suggested that region‐specific diseases in Asia, intrinsic and extrinsic ethnic differences between Japanese/Asian and Caucasian populations, and the status of the drugs’ development in the United States or the European Union all affected Asian GCTs. These factors may infl...
Source: Clinical and Translational Science - November 15, 2017 Category: Biomedical Science Authors: Kunihito Asano, Yoshiaki Uyama, Masahiro Tohkin Tags: ARTICLE Source Type: research
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients
Clinical and Translational Science, EarlyView. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 8, 2017 Category: Biomedical Science Source Type: research
---
Clinical and Translational Science, Ahead of Print. (Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 8, 2017 Category: Biomedical Science Source Type: research
Pharmacokinetics of RP5063 Following Single Doses to Normal Healthy Volunteers and Multiple Doses Over 10 Days to Stable Schizophrenic Patients
Abstract
RP5063, a multimodal dopamine (D)–serotonin (5‐HT) stabilizer, possesses high affinity for D2/3/4 and 5‐HT1A/2A/2B/2C/6/7 receptors and moderate affinity for the serotonin transporter. Two phase I studies characterized the pharmacokinetics of a single dose (10 and 15 mg fasting, 15 mg fed/fasting) in healthy volunteers and multiple doses (10, 20, 50, and 100 mg fed) over 10 days in patients with stable schizophrenia. RP5063 displayed a dose‐dependent Cmax at 4 to 6 h, linear dose proportionality for both Cmax and AUC, and a half‐life between 40 and 71 h. In the single‐dose study, food slightly increase...
Source: Clinical and Translational Science - November 8, 2017 Category: Biomedical Science Authors: Marc Cantillon, Robert Ings, Laxminarayan Bhat Tags: ARTICLE Source Type: research
Issue Information
(Source: Clinical and Translational Science)
Source: Clinical and Translational Science - November 6, 2017 Category: Biomedical Science Tags: ISSUE INFORMATION Source Type: research
Population Pharmacokinetics of Fosdagrocorat (PF ‐04171327), a Dissociated Glucocorticoid Receptor Agonist, in Patients With Rheumatoid Arthritis
Abstract
Dissociated agonists of the glucocorticoid receptor (DAGRs) show similar antiinflammatory effects but improved tolerability compared with standard glucocorticoid receptor (GR) agonists. The prodrug fosdagrocorat (PF‐04171327), with active DAGR metabolite PF‐00251802 (Metabolite‐1), is postulated to show superior efficacy over placebo and prednisone in patients with moderate to severe rheumatoid arthritis (RA). We investigated the population pharmacokinetics of active Metabolite‐1 and its active metabolite PF‐04015475 (Metabolite‐2) in patients with moderate to severe RA enrolled in a 12‐week, phase I...
Source: Clinical and Translational Science - November 4, 2017 Category: Biomedical Science Authors: Barry Weatherley, Lynn McFadyen, Brinda Tammara Tags: ARTICLE Source Type: research
